NZ629898A - Compositions and methods for inhibition of cathepsins - Google Patents

Compositions and methods for inhibition of cathepsins

Info

Publication number
NZ629898A
NZ629898A NZ629898A NZ62989813A NZ629898A NZ 629898 A NZ629898 A NZ 629898A NZ 629898 A NZ629898 A NZ 629898A NZ 62989813 A NZ62989813 A NZ 62989813A NZ 629898 A NZ629898 A NZ 629898A
Authority
NZ
New Zealand
Prior art keywords
thiosemicarbazone
methods
benzene
cathepsins
inhibition
Prior art date
Application number
NZ629898A
Other languages
English (en)
Inventor
David J Chaplin
Devanna Kumar Kishore Gaddale
Erica Parker
Kevin G Pinney
Jiangli Song
Mary L Trawick
Original Assignee
Oxigene Inc
Univ Baylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc, Univ Baylor filed Critical Oxigene Inc
Publication of NZ629898A publication Critical patent/NZ629898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • C07C337/08—Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/784—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
    • C07C49/786—Benzophenone

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ629898A 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins NZ629898A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615091P 2012-03-23 2012-03-23
PCT/US2013/029106 WO2013142038A2 (en) 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins

Publications (1)

Publication Number Publication Date
NZ629898A true NZ629898A (en) 2016-04-29

Family

ID=49223437

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629898A NZ629898A (en) 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins

Country Status (7)

Country Link
US (3) US8877967B2 (https=)
EP (1) EP2828241B1 (https=)
JP (1) JP6231548B2 (https=)
AU (1) AU2013235729B2 (https=)
CA (1) CA2865504A1 (https=)
NZ (1) NZ629898A (https=)
WO (1) WO2013142038A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865504A1 (en) * 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
US9884719B2 (en) 2014-12-12 2018-02-06 Symbotic, LLC Storage and retrieval system
JP6943945B2 (ja) 2016-07-25 2021-10-06 ザ・ボーイング・カンパニーＴｈｅ Ｂｏｅｉｎｇ Ｃｏｍｐａｎｙ エポキシ樹脂
JP7271422B2 (ja) * 2016-12-21 2023-05-11 ソルベイ スペシャルティ ポリマーズ ユーエスエー， エルエルシー ビス（ベンゾイル）ベンゼンを含むモノマー組成物中の金属の濃度を低減させるための方法
US20180198740A1 (en) * 2017-01-06 2018-07-12 David Rademacher System and method for sharing and updating contact information
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
US10487057B1 (en) * 2018-07-05 2019-11-26 Landos Biopharma, Inc. NLRX1 ligands
CN110857267B (zh) * 2018-08-22 2022-12-09 昱镭光电科技股份有限公司 芳香酮化合物及其有机发光器件
US11329823B2 (en) 2019-09-26 2022-05-10 Bank Of America Corporation User authentication using tokens
US11303629B2 (en) 2019-09-26 2022-04-12 Bank Of America Corporation User authentication using tokens

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
CA2058764A1 (en) 1989-04-28 1990-10-29 Peter D. Hodson Dry powder inhalation device
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
SK51695A3 (en) 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
EP0681491B1 (en) 1993-01-29 2000-12-13 Aradigm Corporation Intrapulmonary delivery of hormones
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
AU2001226029A1 (en) 2000-01-10 2001-07-24 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US6897240B2 (en) 2002-05-08 2005-05-24 The Regents Of The University Of California Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
ZA200607582B (en) 2004-03-05 2009-02-25 Univ California Anti-parasitic compounds and methods of their use
US8173696B2 (en) * 2007-06-13 2012-05-08 Baylor University Inhibitors of cysteine proteases and methods of use thereof
EP2379493B1 (en) 2008-12-12 2015-10-14 The University of Melbourne Process for the preparation of asymmetrical bis(thiosemicarbazones)
CA2865504A1 (en) * 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins

Also Published As

Publication number Publication date
JP2015521156A (ja) 2015-07-27
US20130296605A1 (en) 2013-11-07
US9873668B2 (en) 2018-01-23
WO2013142038A2 (en) 2013-09-26
US9458103B2 (en) 2016-10-04
US20150031915A1 (en) 2015-01-29
CA2865504A1 (en) 2013-09-26
AU2013235729A1 (en) 2014-10-09
EP2828241A4 (en) 2016-06-29
US20160368869A1 (en) 2016-12-22
WO2013142038A3 (en) 2015-06-18
EP2828241A2 (en) 2015-01-28
JP6231548B2 (ja) 2017-11-15
US8877967B2 (en) 2014-11-04
EP2828241B1 (en) 2018-09-12
AU2013235729B2 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
NZ629898A (en) Compositions and methods for inhibition of cathepsins
ZA201701299B (en) Glycosidase inhibitors
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018010192A (es) Inhibidores de glucosidasa.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12018500065B1 (en) Oxysterols and methods of use thereof
IN2015DN01156A (https=)
EA201201648A1 (ru) Стимуляторы sgc
EA201290800A1 (ru) Гетероциклическое соединение
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201000098A1 (ru) Производные хиназолинамида
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MX2016002794A (es) Compuestos antiproliferativos.
UA111382C2 (uk) Інгібітори протеїнкінази
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
GEAP201914546A (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015015614A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con el receptor del retinoide (rorc).
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2019 BY CPA GLOBAL

Effective date: 20180303

LAPS Patent lapsed